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Inhibitors of Dipeptidyl Peptidase IV and
Aminopeptidase N Target Major Pathogenetic
Steps in Acne Initiation
Anja Thielitz1, Dirk Reinhold2, Robert Vetter1, Ute Bank3, Martin Helmuth3, Roland Hartig2,
Sabine Wrenger2, Ingrid Wiswedel4, Uwe Lendeckel5, Thilo Ka¨hne5, Klaus Neubert6, Ju¨rgen Faust6,
Christos C. Zouboulis7,8, Siegfried Ansorge3 and Harald Gollnick1
Acne is a chronic disease hallmarked by sebaceous hyperplasia, follicular hyperkeratosis, and inflammation.
Parallel targeting of these factors is required to treat acne effectively. Inhibitors of dipeptidyl peptidase IV (DP
IV) and aminopeptidase N (APN) show strong anti-inflammatory effects on immune cells and therapeutic
efficacy in autoimmune disorders. Our investigation focused on the expression and functional relevance of
these ectopeptidases in three cell types which exhibit an altered phenotype in early acne lesions. We showed
for the first time expression of DP IV and APN on human sebocytes. In the SZ95 sebocyte cell line, the DP IV
inhibitors Lys[Z(NO2)]-thiazolidide and Lys[Z(NO2)]-pyrrolidide and the APN inhibitors actinonin and bestatin
suppressed proliferation, enhanced terminal differentiation, and slightly decreased total neutral lipid
production. The anti-inflammatory and differentiation-restoring cytokine IL-1 receptor antagonist was
significantly upregulated in SZ95 sebocytes and the HaCaT keratinocyte cell line in the presence of inhibitors.
Furthermore, the inhibitors suppressed proliferation and IL-2 production of Propionibacterium acnes-
stimulated T cells ex vivo and enhanced the expression of the immunosuppressive cytokine transforming
growth factor-b1. Our data provide first evidence for a functional role of DP IV and APN in the sebaceous gland
apparatus and for their inhibitors, used alone or in combination, as completely new substances possibly
affecting acne pathogenesis in a therapeutic manner.
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INTRODUCTION
Acne vulgaris is the most common skin disease worldwide.
Intense medical treatment is needed in acne patients to prevent
physical or psychological scarring, and annual costs for health
care in acne exceed $1 billion in the US alone (Stern, 2000).
Treatment efficacy is significantly enhanced by the combination
of various agents to target the major pathogenetic factors in
parallel (Gollnick et al., 2003; Leyden, 2003); and the use of
isotretinoin affecting four major pathogenetic factors is clini-
cally limited owing to teratogenicity and side effects (McLane,
2001). Thus, the development of new therapeutic strategies
overcoming the current limitations is clinically required.
Ectopeptidases are ubiquitously expressed and have
pleiotropic functions (Antczak et al., 2001). Interaction
with agonistic antibodies or inhibitors revealed that ecto-
enzymes, beyond their proteolytic activity, influence funda-
mental biological processes such as growth, apoptosis,
differentiation, adhesion, motility, invasion, cell–cell inter-
action, angiogenesis, and transformation (De Meester et al.,
1999; Iwata and Morimoto, 1999; Riemann et al., 1999).
This implies a possible role of these enzymes as targets to
influence pathophysiologic conditions. The pharmacological
inhibition of dipeptidyl peptidase IV (DP IV) (EC 3.4.14.5.,
DP IV, CD26) as well as aminopeptidase N (APN) (EC
3.4.11.2, membrane alanyl-aminopeptidase (mAAP), APN,
CD13) affects growth, cytokine production, and typical
functions of human peripheral T cells both in vitro and
in vivo (Reinhold et al., 1997, 2002; Lendeckel et al., 1999).
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Inhibitors of DP IV have potent immunosuppressive and
anti-inflammatory effects in various disease models such as
murine experimental autoimmune encephalomyelitis (Stein-
brecher et al., 2001), collagen- and alkyldiamone-induced
arthritis (Tanaka et al., 1997), and rat cardiac transplantation
(Korom et al., 1997), and are presently undergoing clinical
phase II and III trials (McIntosh et al., 2005) for type II diabetes.
APN inhibitors have shown therapeutic efficacy in analge-
sia models and tumor neoangiogenesis (Fournie´-Zaluski and
Roques, 2002), and bestatin (B) is clinically used as an
immunomodulator in cancer patients (Fujisaki et al., 2003).
The skin represents an interesting new target organ of
ectopeptidase inhibitors, not only because skin diseases
involve the activation of immune cells but also because both
DP IV and APN are expressed on human keratinocytes in vivo
and upregulated in hyperproliferative skin diseases, for
example, psoriasis (Hunyadi et al., 1993; Novelli et al.,
1996). Previous investigations showed that inhibitors of DP IV
and APN suppress keratinocyte proliferation in vitro (Reinhold
et al., 1998; Gabrilovac et al., 2004) and partially restored
keratinocyte differentiation in vivo (Thielitz et al., 2004).
Thus multifactorial diseases hallmarked by hyperprolifera-
tion and inflammation such as acne are promising research
fields for therapeutic applications of ectopeptidase inhibitors.
Our knowledge about the pathogenetic steps leading to
acne initiation is still incomplete and subject of controversial
discussion (Zouboulis et al., 2005). The beginning of micro-
comedone formation is associated with aberrant differentiation
of the follicular epithelium (Kurokawa et al., 1988; Norris and
Cunliffe, 1988), vascular endothelial cell activation, and
inflammatory events (Jeremy et al., 2003), which supports
the hypothesis that acne may represent a genuine inflamma-
tory disease. The sequence of events initiating ductal
hypercornification is not yet elucidated, and hypotheses
implicate changes in sebum lipid composition (Downing
et al., 1986), androgenic stimulation (Thiboutot et al., 1997),
and immunologic stimulation in keratinocytes triggered by
Propionibacterium acnes (P. acnes) (Nagy et al., 2005).
Future acne treatment should focus on targeting the very
early steps of acne lesion development and thus normalize
the primary pathogenetic factors to induce microcomedones,
which are hyperproliferation of sebocytes and consecutive
hyperseborrhea and hyperproliferation of follicular keratino-
cytes (Gollnick, 2003) as well as inflammatory processes
such as specific immune responses toward P. acnes antigens
(Mouser et al., 2003) or intrinsic generation of inflammation
within the sebaceous glands (Zouboulis et al., 2003, 2005).
The aim of our present work was to investigate the
expression and functional relevance of DP IV and APN as a
new target complex on three cell types implicated in acne
pathogenesis to lay the foundation of inhibitor-based future
acne therapy.
RESULTS
Expression of DP IV, CD26 and APN, CD13 on human
sebocytes
Using the human-immortalized sebaceous gland cell line
SZ95 to assess the effects of inhibitors on human sebaceous
function, we show for the first time at the levels of mRNA
(Figure 1a), protein (Figure 1b and c), and enzymatic activity
(DP IV¼Gly-Pro pNA hydrolyzing activity 3779 pkat/
106 cells and APN¼Ala-pNA hydrolysing activity
205754 pkat/106 cells) that the ectopeptidases DP IV/CD26
and APN/CD13 are expressed on human sebocytes. The DP
IV activity of SZ95 sebocytes was found to be 6-fold higher
than that of resting peripheral blood T cells (672 pkat/
106 cells; Ka¨hne et al., 1999) and 2-fold higher than that of
T cells stimulated for 48 hours with phytohemagglutinin
(PHA), whereas APN activity exceeded that of PHA-activated
T cells (31.472.8 pkat/106 cells; Lendeckel et al., 1999) by
6- to 7-fold. Flow cytometric studies (Figure 1b) and direct
immunofluorescence staining (Figure 1c) revealed high
surface expression of both ectopeptidases, with 9871%
CD26-positive cells and 100% CD13-positive cells.
The immunohistochemical staining of human scalp sec-
tions demonstrated a positive, but slightly different expression
pattern of both ectopeptidases in sebaceous glands; CD26 is
generally stronger expressed and mainly localized in basal
low-differentiated sebocytes in the periphery of the glands
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Figure 1. Expression of DP IV/CD26 and APN/CD13 on human SZ95
sebocytes. (a) mRNA expression of DP IV and APN. Enzymatic amplification
was performed on cDNA derived from 70 to 80% confluent cell cultures.
(b) CD26 and CD13 surface expression detected by flow cytometry. (c) Direct
immunofluorescence staining (top) and light microscopic control (bottom)
of vital SZ95 sebocytes attached to poly-L-lysine-coated cover slides.
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(Figure 2i and l), whereas CD13 presents a more diffuse
staining pattern in the periphery (Figure 2h and k) as well as
in clusters in the center of the glands, which have been
described previously (Cunliffe, 1992) as highly proliferating
cells and represent undifferentiated cells sitting on the base
of septa separating the lobules of the gland. Further-
more, positive expression could be shown in the epidermis
(Figure 2b and c), the hair follicle (Figure 2e and f) as well as
in smooth musculature (Figure 2h and i).
Inhibitors of DP IV and APN suppress enzyme activity and DNA
synthesis of SZ95 sebocytes in vitro
The DP IV inhibitors Lys[Z(NO2)]-thiazolidide (LZNT)
and Lys[Z(NO2)]-pyrrolidide (LZNP), and the APN inhi-
bitors actinonin and B, were capable of significantly
(Po0.001) suppressing enzymatic activity in a dose-
dependent manner (Figure 3a and b). No significant
differences could be detected between inhibitors of either
DP IV or APN.
The DNA synthesis of viable SZ95 sebocytes after 48 hours
incubation in the presence of different inhibitor concen-
trations was rapidly and dose-dependently (Po0.0001)
suppressed (Figure 3c and d) compared to control cultures
without inhibitor, which correlated with the reduction in
enzyme activity. The retinoid with the most potent effects on
the proliferation of sebocytes, 13-cis-retinoic acid (13-cis-
RA), significantly suppressed SZ95 proliferation at 105 and
106 M (Po0.001), but not at 107 M (Figure 3c).
The antiproliferative effect was partly enhanced in an
additive manner by the combination of inhibitors of DP IV
and APN, which is demonstrated for the combination of
LZNT and the most potent single inhibitor, actinonin
(Figure 3d). Table 1 summarizes the inhibitory concentra-
tion of 25% suppression of DNA synthesis calculated
from the mean of 6 different experiments (or inhibitory
concentration of 75% suppression of DNA synthesis calcu-
lated from the mean of 6 different experiments, respectively)
and inhibitory concentration of 50% suppression of DNA
synthesis calculated from the mean of 6 different experi-
ments values of SZ95 obtained for the single and combined
inhibitors, compared to HaCaT, primary keratinocytes,
and P. acnes-stimulated peripheral blood mononuclear cells
(PBMCs).
Possible cytotoxic side effects of the inhibitors in the
concentrations used could be excluded using the lactate
dehydrogenase cytotoxicity detection assay, and by trypan
blue staining, which demonstrated more than 95% viable
cells in all culture systems 6 hours after inhibitor incubation
(data not shown).
a b c
d e f
g h i
j k l
Figure 2. Detection of CD26- and CD13-positive cells in the pilosebaceous
follicle. Deparaffinized sections of human scalp preteated with Proteinase K
were stained with (a–j, left panel) an IgG-control or (b–k, middle panel) the
anti-CD13 antibody My7 or (c–l, right panel) the anti-CD26 antibody BA5 and
visualized by the immunoperoxidase technique (red, immunoreactivity).
Arrows indicate (b, c) positive labelling in the epidermis, (e, f) the hair follicle,
(h, i) smooth musculature, and (h, i, k, l) within the sebaceous glands. (a–c, j–l)
Bar¼0.1 mm and (d–f, g–i) 0.2 mm.
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Figure 3. Suppression of enzymatic activity and proliferation of SZ95
sebocytes in the presence of inhibitors. (a) and (c) The inhibitors of DP IV
LZNP and LZNT dose-dependently (Po0.001) (a) reduce enzymatic activity
(Gly-Pro-pNA hydrolysis) and (c) DNA synthesis (Po0.001) measured by
[3H]thymidine incorporation. (b) and (d) The APN inhibitors actinonin and B
suppress both the (b) enzymatic activity (Ala-pNA hydrolysis) and (d) DNA
synthesis in a dose-dependent manner (Po0.001). The enzymatic activity
represents the mean7SEM of four independent experiments; statistics
were calculated using the General linear model procedure of SAS 8.2.
The DNA synthesis values are expressed as percentage of [3H]thymidine
incorporation in relation to control cultures without inhibitor
(100%¼ 16,04771,773 c.p.m.) and represent the mean7SEM of six
independent experiments. (c) 13-cis-RA significantly suppressed DNA
synthesis compared to control cultures (0 mM) at 10 and 1 mM (Po0.001),
but not at 0.1 mM. The retinoid effect was not dose-dependent.
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Inhibitors of DP IV and APN induce terminal differentiation in
SZ95 sebocytes
Sebocyte differentiation is characterized by increasing cell
size, granularity, and lipid content. To assess inhibitor effects
on sebaceous differentiation, we used a flow cytometric
Nile Red fluorescence assay, which indicated the neutral
lipid content per cell. We showed that incubation of
SZ95 sebocytes with inhibitors for 48 hours produces a
dose-dependent increase in sebocyte differentiation (Figure
4a). The effects on terminal differentiation correspond well
with the antiproliferative effects of the single inhibitors,
with actinonin as single inhibitor and a combination of
LZNT and actinonin showing the greatest capacity to
influence both parameters. 13-cis-RA significantly suppressed
sebocyte differentiation only at 107 M (Po0.05), a concen-
tration where the proliferation was not affected.
We then attempted to ascertain the extent to which the
inhibitors influenced the neutral-lipid composition of sebo-
cytes. Therefore, we measured the cholesterol, free fatty
acids, triglycerides, wax esters, and squalene fractions of
confluent SZ95 sebocytes using high-performance thin layer
chromatography after an incubation period of 48 hours in the
presence of each of the four inhibitors separately and a
combination of the most potent inhibitors, at a concentration
of 50 mM. Squalene was not detectable in our system, and the
amounts of triglycerides and wax esters were low, which
indicates that the differentiation grade of cultured sebocytes
is lower as compared to freshly isolated cells. Despite the
increase of single-cell differentiation seen in the Nile Red
assay, the total neutral lipid content of the cultured cells
showed a trend for a decrease (Figure 4b), which was not
statistically significant. The relative composition of neutral
lipids (Figure 4b) as well as free fatty acids analyzed by gas
chromatography (data not shown) was not significantly
altered in inhibitor-treated cultures; however, a trend for a
decrease in the (saturated) free fatty acid fraction was
Table 1. DP IV and APN inhibitors suppress DNA synthesis in different cell types
SZ 95 HaCaT PKC PBMC (PA)
Inhibitor IC25
1 IC50
2 IC25
1 IC50
2 IC25
1 IC50
2 IC50
2 IC75
3
LZNP 5 92 12 4100 22 — 6 15
LZNT 2.5 55 8 55 20 100 3 7.5
Actinonin 2.5 36 6.5 23 4 — 4 —
Bestatin 3 — 37 — 21 — 3 6
LZNP+A 1.25 12 2.5 12 3 4100 1.25 2.5
LZNT+A 1 11 2.5 10 2.5 50 1.25 2
LZNP+B 1.25 20 8 4100 3 4100 1.25 3.5
LZNT+B 1.25 15 6.25 32 3 58 1.75 2
A, actinonin; APN, aminopeptidase N; B, bestanin; DP IV, dipeptidyl peptidase IV; LZNP, Lys[Z(NO2)]-pyrrolidide; LZNT, Lys[Z(NO2)]-thiazolidide;
PA, P. acnes; PKC, primary keratinocyte; PBMC, peripheral blood mononuclear cell.
1IC25=inhibitory concentration of 25% suppression of DNA synthesis calculated from the mean of six different experiments.
2IC50=inhibitory concentration of 50% suppression of DNA synthesis calculated from the mean of six different experiments.
3IC75=inhibitory concentration of 75% suppression of DNA synthesis calculated from the mean of six different experiments.
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Figure 4. Influence of DP IV and APN inhibitors on sebocyte differentiation
and neutral lipid composition. (a) Inhibitor-induced (left part) or 13-cis-RA-
induced (right part) dose-dependent relative increase of terminal differentia-
tion per cell for SZ95 sebocytes measured by Nile Red fluorescence intensity
detected after 48 hours of incubation. The data are demonstrated relatively to
control (without inhibitor or retinoid) and represent the mean7SEM of seven
independent experiments. Linoleic acid served as positive control (*Po0.05,
***Po0.001, Dunnett’s multiple comparison test). (b) Reduction of total
neutral lipid content and relative composition of neutral lipids extracted from
confluent SZ95 cell cultures in the presence of DP IV and APN inhibitors at
50mM or of 13-cis-RA at 107 M after 48 hours of incubation. Values are
demonstrated relatively to control and represent the mean of six experiments.
WE, wax esters; TG, triglycerides; FFA, free fatty acids; CH, cholesterol.
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detectable in the presence of inhibitors. In the presence of
13-cis-RA tested as a control substance at concentrations
105–107 M, no change in the neutral lipid amounts after
48 hours could be detected. Figure 4b includes the concen-
tration with the strongest effect on lipid production (107 M,
concentrations 105 and 106 M not shown), which is
corresponds to the results obtained in the differentiation
assay (Figure 4a).
DP IV and APN inhibitors enhance IL-1RA production
in sebocytes and keratinocytes
Sebocytes are able to produce proinflammatory cytokines
such as tumor necrosis factor-alpha, IL-1a, and IL-1b (Boehm
et al., 1995). Therefore, we investigated inhibitor effects on
the production of these proinflammatory cytokines and the
antagonist interleukin-1 receptor antagonist (IL-1RA) in SZ95
sebocytes, and we additionally measured IL-1RA production
of HaCaT and primary keratinocytes.
In SZ95 sebocyte supernatants, very low amounts of IL-1a
(maximum 17 pg/ml), and IL-1b (maximum 4 pg/ml) were
found, whereas tumor necrosis factor-alpha was not detect-
able. The amounts of these cytokines were not significantly
changed in the presence of the inhibitors (data not shown).
However, we found a strong expression of IL-1RA protein in
control supernatants (1,1187204 pg/ml), which was slightly
but significantly increased in the presence of each of the four
inhibitors (1.3- to 1.7-fold at 50 mM; 1.7- to 2.4-fold at 100mM,
data not shown) after 48 hours incubation (Po0.05). Similar
results were obtained at a lower base level (153735 pg/ml)
in HaCaT keratinocytes (1.3- to 1.7-fold increase at 50 mM,
1.5- to 2.4-fold at 100mM, data not shown).
To further investigate the regulation of IL-1RA, we applied
the most potent single inhibitors LZNT and actinonin (50 mM
each) as well as their combination and measured the IL-1RA
protein levels and mRNA levels at different time points
after the inhibitor was added. We found a time-dependent
increase of IL-1RA on the protein level (Po0.001). Compar-
ing the inhibitor effects at the different time points, we found
a trend for an additive effect of the inhibitor combination,
comparable to the observed effects on proliferation demon-
strated in Table 1 and Figure 3d; however, a statistically
significant difference between the combination and the most
potent single inhibitor could be demonstrated only in HaCaT
keratinocytes on the mRNA level 3 hours after inhibitor
incubation (Figure 5d).
In general, the effect was maximum after 48 hours on the
protein levels in SZ95 sebocytes (Figure 5a) and HaCaT
keratinocytes (Figure 5b), and maximum after 3 hours on the
mRNA levels, with increases of up to 4-fold in SZ95
sebocytes (Figure 5c) and 2.6-fold in HaCaT keratinocytes
(Figure 5d).
Inhibitors of DP IV and APN suppress DNA synthesis and IL-2
production of P. acnes-stimulated PBMC and induce TGF-b1
production in vitro
PBMC from 16 donors with or without a history of acne
showed a significantly increased but varying proliferative
response after stimulation with P. acnes antigen (Figure 6a),
which was even in less responding subjects slightly increased
as compared to unstimulated controls, probably indicating
a previously described weak mitogenic effect of P. acnes
antigen (Jappe et al., 2002). PBMC from different donors
showed equal rates of DNA synthesis after stimulation with
the mitogen PHA, which were higher in comparison to those
obtained with antigen-stimulated cells.
Furthermore, we studied the effects of the DP IV and
APN inhibitors on P. acnes antigen-stimulated DNA synthesis
of subjects showing a markedly increased proliferative
response (stimulation index 45). In accordance to previous
data obtained from mitogen-stimulated PBMC and T cells, we
found strong dose-dependent (Po0.001) antiproliferative
activities for each of the four inhibitors or combinations of
a DP IV and APN inhibitor used in a concentration range of
1–20 mM on P. acnes antigen-stimulated PBMC (Figure 6b and
d). Moreover, we demonstrated a significant decrease in IL-2
production (Po0.01) and an increase in the production of the
immunosuppressive cytokine transforming growth factor b1
(TGF-b1) after 24 hours in the presence of each DP IV and
APN inhibitor used in concentrations of 10mM (Figure 6c).
With regard to the cytokine production, the combination
showed no significant additive effect as compared to the
single inhibitors.
DISCUSSION
The design of an ideal future acne treatment is subject of
controversial discussion (Zouboulis et al., 2005) because our
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Figure 5. DP IV and APN inhibitors increase IL-1RA expression in SZ95
sebocytes and HaCaT keratinocytes. (a, b) Increase of IL-1RA protein
expression in supernatants of (a) SZ95 sebocytes and (b) HaCaT keratinocytes
at 3, 24, and 48 hours after inhibitor incubation. The data represent the
mean7SEM of four independent experiments. Statistics were calculated
separately at each time point, asterisks indicate significance compared to
control without inhibitor (*Po0.05; **Po0.01 Tukey’s multiple comparison
test). (c, d) Increase of IL-1RA mRNA amounts detected by quantitative real-
time PCR in (c) SZ95 sebocytes and (d) HaCaT keratinocytes. The bars
represent the mean7SEM of six independent experiments. The data are
presented as relative amounts compared with the control or as indicated
(*Po0.05, **Po0.01 Tukey’s multiple comparison test).
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knowledge about the relative contribution of various factors
to acne initiation is still incomplete. Based on clinical
experience supported by the efficacy of oral isotretinoin
and combination therapy, parallel targeting of sebaceous
hyperplasia, follicular hyperkeratosis, and inflammation
represents the most promising approach to treat acne.
The presented data demonstrate that inhibitors of the
ectopeptidases DP IV or APN have the capacity to influence
exactly these major pathogenetic factors of acne in vitro.
They profoundly affect proliferation and cytokine balance of
three cell types with observed alterations in early acne
pathogenesis by antagonizing hyperproliferation of sebocytes
leading to hyperseborrhea, hyperproliferation of keratino-
cytes inducing follicular hyperkeratosis, and proliferation of
immune cells being part of a specific immune response
toward P. acnes antigen.
We showed for the first time that DP IV and APN are
highly expressed on the surface of human SZ95 sebocytes
in vitro, suggesting that sebocytes could be effectively
targeted by peptidase inhibitors. As animal models in acne
failed to predict pharmacological outcomes in humans, we
used the immortalized human sebaceous gland cell line SZ95
for the investigations on human sebaceous function. In vivo
expression was detected by immunohistochemistry of human
scalp sections and revealed positive staining, especially
in undifferentiated, highly proliferating (Cunliffe, 1992)
sebocytes at the periphery of the sebaceous lobules, which
have been considered to be the ‘‘regenerative pool’’ of the
glands. Previous research revealed that the skin expression
of both enzymes is not constant but regulated in an age-
dependent manner (Sorrell et al., 2003). Thus, the next
experimental step will be to further investigate the differential
expression of the ectopeptidases in inflammatory acne lesions
to delineate pathophysiological significance and better
predict the possible therapeutical efficacy in vivo. This is of
particular interest because the ectopeptidase neutral endo-
peptidase (NEP; CD10; EC 3.4.24.11), which is often
coexpressed with DP IV and APN in vivo (Riemann et al.,
1999), has been reported to be significantly upregulated in
acne patients but was not detectable in sebaceous glands of
healthy subjects (Toyoda et al., 2002).
Our results demonstrate that inhibitors of both DP IV/
CD26 and APN/CD13 significantly suppress enzyme activity
and SZ95 sebocyte proliferation in a dose-dependent
manner. Comparable effects could be obtained at the same
time point with 13-cis RA only in concentrations of 106 M or
higher (Figure 3c).
The suppression of proliferation is inversely correlated
with an induction of terminal differentiation of sebocytes,
which is characterized by increasing size, accumulation of
lipid droplets, and nuclear degeneration (Wro´bel et al.,
2003). It is conceivable that the balance between antiproli-
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Figure 6. Effects of inhibitors on proliferation and cytokine production of P. acnes antigen-stimulated PBMCs. (a) Stimulation indices of P. acnes antigen-
stimulated PBMCs compared to mitogen (PHA)-stimulated PBMCs of 16 adult subjects. (b, d) Dose-dependent suppression (Po0.001) of DNA synthesis of P.
acnes antigen-stimulated PBMCs in the presence of DP IV and APN inhibitors and their combination at concentrations of 0.62–20 mM. [3H]thymidine
incorporation is indicated as mean7SD of six independent experiments. Values are expressed as percentage of [3H]thymidine incorporation in relation to
control cultures without inhibitors (100%¼ 8,98673,109 c.p.m.). (c) Absolute inhibitor-induced changes in cytokine levels detected in PBMC supernatants after
24 hours at a concentration of 10mM: increase of latent TGF-b1 and suppression of IL-2 relative to control cultures without inhibitors. Values represent the
mean7SD of three different experiments. Statistics were calculated related to the control (*Po0.05, **Po0.01, Dunnett’s multiple comparison test).
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ferative and prodifferentiative effects will not induce hyper-
seborrhea, because despite an increase in the single-cell lipid
content by enhanced differentiation (Figure 4a), the total
neutral lipid collected from cells cultivated for 2 days in
the presence of inhibitors tends to decrease after a short
incubation period (Figure 4b). It is tempting to speculate that
the block in cellular proliferation of undifferentiated cells
leads to an accelerated normal differentiation process,
which ends up with apoptosis/holocrine secretion. This is
also corroborated by increased nuclear fragmentation in-
dices, which we observed in the presence of inhibitors (data
not shown). Interestingly, 13-cis-RA induced no significant
decrease in differentiation at concentrations with a marked
antiproliferative effect, which further supports the hypothesis
that both processes might be inversely related. The signifi-
cance of these inhibitors effects on the complex human
sebaceous function in vivo remains to be established.
The proinflammatory cytokine IL-1a represents another
hallmark in early acne pathogenesis. Increased levels can
be found in uninvolved follicles, early acne lesions (Aldana
et al., 1998; Jeremy et al., 2003), and abundantly in extracted
mature comedones (Ingham et al., 1992). Its functional
relevance was studied in an in vitro organ model, where it
induced a follicular hyperkeratosis in isolated sebaceous
infundibula (Guy et al., 1996). This process could be blocked
or reversed by the application of IL-1RA, indicating that the
ratio of IL-1a/IL-1RA is involved in regulating growth and
differentiation of keratinocytes. It is likely that keratinocytes
are one major source of the increased IL-1 levels around
acne follicles, which might be induced by P. acnes or
P. acnes heat-shock proteins (Graham et al., 2004). Sebocytes
‘‘stressed’’ in vitro produced IL-1a on the mRNA and protein
level (Zouboulis et al., 1998), and in vivo investigations
detected presence of IL-1a immunoreactivity and mRNA in
sebaceous glands (Anttila et al., 1992; Boehm et al., 1995).
We demonstrated that inhibitors of DP IV and APN slightly
but significantly increase the expression of the anti-inflam-
matory cytokine IL-1RA in sebocytes and keratinocytes, both
being possible sources of IL-1a in vivo. Variations in the IL1-
RA/IL-1a ratio during keratinocyte cell cycle (Hammerberg
et al., 1998) would provide one possible mechanism for
our previously observed inhibitor effects on keratinocyte
proliferation and differentiation in vitro and in vivo (Thielitz
et al., 2004).
Interestingly, simultaneous inhibition of both enzymes
exhibited partially additive effects on the proliferation, but
not cytokine production, in different cell types (Figures 3d
and 6b, d; Table 1). With regard to the development of
therapeutic agents, the application of an inhibitor combina-
tion might be useful, because synergistic effects have been
reported on T cells in vitro (Lendeckel et al., 2003) and in
vivo (Bank et al., 2006; Biton et al., 2006).
The molecular basis of antiproliferative and immuno-
modulating effects of DP IV or APN inhibitors are only partly
understood (von Bonin et al., 1998; Lendeckel et al., 1999,
2000; Reinhold et al., 2005). One important observed
mechanism in T cells, the release of TGF-b1 4–6 hours after
inhibitor treatment (Ka¨hne et al., 1999), leads to an arrest in
the cell cycle at G1 (Polyak et al., 1994) and partly explains
the observed suppression of T-cell proliferation, which we
could also demonstrate in P. acnes-stimulated PBMC.
The pathophysiologic role of T cells found in uninvolved
follicles before any detectable signs of keratinocyte hyper-
proliferation is yet unclear, but their further accumulation in
acne lesion progress (Layton et al., 1998) in coincidence
with other histologic hallmarks of immunologic/vascular
activation strongly suggests a functional contribution to
disease aggravation. Within the increased perifollicular
CD4þ T-cell population, the majority consisted of mem-
ory/effector (CD45RO) cells, with a similar proportion
exhibiting a skin-homing phenotype (Jeremy et al., 2003),
suggesting a specific antigenic response. Human T-cell
clones isolated from lesional acne skin showed a significant
increase in proliferation and IFN-g production in response
to P. acnes stimulation, which could not be achieved with
psoriatic T-cell lines or in presence of other skin commensals
(Mouser et al., 2003). Our results demonstrate that inhibitors
of DP IV and APN strongly suppress the T-cell proliferation
in response to P. acnes antigenic stimulation of PBMC and
additionally shift the cytokine production toward an anti-
inflammatory phenotype.
In summary, our results provide first in vitro evidence for
inhibitors of DP IV and APN as a new substance class
with the capacity to influence three major pathogenetic
factors of acne: sebaceous hyperplasia, follicular hyper-
keratosis, and (early) inflammation.
The presented data suggest that the single or parallel
inhibition of DP IV and APN might represent a promising and
novel therapeutic strategy for this global disease. Clinical
trials using newly designed highly specific inhibitors will be
necessary to confirm these intriguing findings in vivo.
MATERIALS AND METHODS
All described studies using materials obtained from human subjects
were conducted according to the Declaration of Helsinki Principles
and approved from the medical ethical committee of the Otto-von-
Guericke University, Magdeburg, Germany. Participants gave their
written informed consent.
Cell culture conditions
PBMCs were isolated by density-gradient centrifugation over Ficoll
Paque gradients as described previously (Reinhold et al., 1997) and
seeded at a density of 105 cells/100 ml in serum-free AIM-V medium
(Invitrogen, Karlsruhe, Germany). They were stimulated with heat-
inactivated (801C, 30 minutes) P. acnes protein suspensions in a
concentration of 10 mg/ml, obtained from the P. acnes strain DSM
20458 (DMSZ Braunschweig, Germany) cultured for 3 days in
differential clostridial broth (Merck, Darmstadt, Germany) to reach
stationary growth phase. The culture was centrifuged at 16,000 g
at 41C and the pellet resuspended in phosphate-buffered saline
(Biochrom Berlin, Germany) for protein determination. Unstimu-
lated PBMC and PHA-stimulated (PHA, 1 mg/ml, Abbott, Wiesbaden,
Germany) PBMC served as controls.
HaCaT keratinocytes were maintained in serum-free medium
(Keratinocyte-SFM, Invitrogen, Karlsruhe, Germany) and SZ95
sebocytes (Zouboulis et al., 1999) in Sebomed Basal Medium
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(Biochrom) supplemented with 10% heat-inactivated fetal bovine
serum, antibiotics, 5 ng/ml human epidermal growth factor (Promo-
cell, Heidelberg, Germany), and CaCl2 (Sigma-Aldrich, Deisenhofen,
Germany) to obtain a final concentration of 1 mM. All experiments
using peptidase inhibitors were performed in serum-free medium
(Sebomed Complete Medium, Biochrom). Actinonin and B were
obtained from Sigma-Aldrich (Deisenhofen, Germany). LZNP
and LZNT were synthesized by K. Neubert and J. Faust. Cell
viability was determined using the lactate dehydrogenase cytotoxi-
city detection kit (Roche Diagnostics, Mannheim, Germany) at time
points of 4 and 6 hours after inhibitor incubation and by trypan
blue (Sigma-Aldrich) staining.
RNA preparation from SZ 95 and HaCaT and qualitative RNA
amplification
Total RNA from 1 106 cells was prepared using the RNeasy Kit
provided by Qiagen (Hilden, Germany) following the recommended
protocol. The resulting RNA was quantified spectrophotometrically
using a GeneQuant (Pharmacia, Freiburg, Germany), aliquoted, and
stored ethanol-precipitated at 801C until further use.
One microgram of total RNA was transcribed in a 20 ml
reaction mixture containing 20 U of avian myeloblastosis virus
reverse transcriptase (Promega, Mannheim, Germany) in the
supplied buffer, 0.5 mmol/l desoxynucleoside triphosphates,
10 mmol/l random hexanucleotides (Boehringer, Mannheim,
Germany), and 50 U of placenta RNase inhibitor (Ambion,
Austin, USA).
Reverse transcription reaction (1.2 ml) was used as template for
amplification. Forty cycles were performed in a Peltier thermal
cycler PTC-200 (Biozym Diagnostik, Hessisch Oldendorf, Germany)
in 50 ml reaction buffer containing 2.5 U HotStarTaqTM DNA
Polymerase (Qiagen, Hilden, Germany), 200 mM dNTP, and 0.5 mM
of the corresponding RT primer set of APN (upstream, 50-gTCTACTg
CAACCTATCg; downstream, 50-gATggACACATgTgggCACC) and DP
IV (upstream, 50-gATgCTACAgCTgACAgTCgC; downstream, 50-Tgg
TgACCATgTgACCCACTg) obtained from BioTeZ (Berlin, Germany).
The initial activation step at 951C for 15 minutes was followed by 40
cycles of denaturing for 1 minutes at 941C, annealing for 0.5 minutes
at 601C, and extension at 701C for 1 minute. The reaction was
stopped after a final extension step at 721C for 5 minutes and
products visualized on a 1.5% agarose gel.
RNA quantification
Quantitative PCR was performed using the iCycler (real-time PCR
device, Bio-Rad, Munich, Germany). For IL-1RA determination, the
25 ml reaction mixture consisted of 12.5 ml QuantiTectTM-SYBR-
GreenTM-Master-Mix (Qiagen, Hilden, Germany), 1 ml of the reverse
transcription reaction, and 0.5 mmol/l of the specific primers for
IL-1RA (upstream, 50-gggAgAAAATCCAgCAAg; downstream, 50-TgA
CACAggACAggCACAT) synthesized by Jenabioscience (Jena,
Germany). Initial denaturation and activation of Taq polymerase at
951C for 15 minutes was followed by 42 cycles with denaturation at
941C for 30 seconds, annealing at 551C for 48 s, and elongation at
721C for 36 s. Amounts of 18S mRNA were determined using the RT
primer pair available from Ambion and used to normalize cDNA
contents. The fluorescence intensity of the double-strand-specific
SYBR-Green I, reflecting the amount of actually formed PCR
product, was read real-time at the end of each elongation step.
Data are given as arbitrary units normalized to 18S RNA amounts.
All samples were analyzed in triplicate.
Immunofluorescence staining of cells
Immunofluorescence staining of SZ 95 cells was performed using the
monoclonal anti-CD13 antibody WM15 and the monoclonal anti-
CD26 antibody clone M-A261 (both mIgG1, BectonDickinson
Biosciences, Heidelberg, Germany). For control of nonspecific
labelling, we tested the binding of an irrelevant IgG1 monoclonal
mouse antibody (BectonDickinson Biosciences). Labelled cells were
analyzed by flow cytometry (FACS-Calibur, BectonDickinson
Biosciences) and visualized after attachment to poly-L-lysine-coated
cover slides using the confocal laser scan microscope Leica TCS SP2
(Leica Camera AG, Solms, Germany).
Immunohistochemistry
Deparaffinized sections from 6-mm human scalp punch biopsies
were incubated with Proteinase K solution (DakoCytomation
GmbH, Hamburg, Germany) for 1 minutes, washed three times in
Tris-buffered saline solution containing 0.05% Tween 20, pH 7.6,
and consecutively stained with the monoclonal antibodies My7
(anti-CD13, mIgG1, 1:25, BeckmannCoulter, Krefeld, Germany,
60 minutes) and BA5 (anti-CD26, mIgG2a, 1:25, BeckmannCoulter,
30 minutes). Negative controls included incubation with an isotype-
specific control (mIgG, 1:25, BeckmannCoulter, 30 minutes) and
omission of the first antibody.
The consecutive steps were performed using standard immuno-
peroxidase techniques following the protocol of the LSAB-2 System-
AP staining kit (DakoCytomation). Slides were incubated for
20 minutes in the dark with the chromogenic substrate Fast
RED, rinsed with and then placed for 10 minutes in distilled
water, and finally counterstained with Mayer’s hematoxylin
(10 seconds) before mounting in Faramount Aequous Mounting
Medium (DakoCytomation).
Enzymatic assay
Enzymatic activity of APN was determined in triplicate in phosphate-
buffered saline, pH 7.4, using Ala-4 nitroanilide (Ala-pNA, Sigma-
Aldrich, Deisenhofen, Germany) as chromogenic substrate. Ala-pNA
(100ml) were added in a concentration of 5 mM to cellular
suspensions of 105 cells/100 ml. Reactions were stopped by adding
900ml acetate buffer (1 M, pH 4.4) either immediately (control) or
after 60 minutes of incubation at 371. After centrifugation (2 minutes;
10,000 g), the absorbance of the supernatant was detected
spectrophometrically at 392 nm. Enzymatic activity of DP IV was
determined after 120 minutes of incubation using 3 mM Gly-Pro-
4-nitroanilide (Gly-Pro-pNA, Sigma-Aldrich) added to cellular
suspensions.
Proliferation assay
HaCaT keratinocytes, SZ95 sebocytes (1 105 cells/ml), and PBMCs
(1 106/ml) were seeded in 96-well plates (Nunc, Wiesbaden,
Germany) in serum-free medium. PBMCs obtained from 16 donors
were stimulated either with P. acnes protein (10 mg/ml) or PHA (1mg/
ml) or left unstimulated. The stimulation index was calculated as
mean counts per minute (c.p.m.)/c.p.m. of unstimulated control
cultures. Different concentrations of the inhibitors (3.125–50 mM)
actinonin, B, LZNT, and LZNP or a combination of DP IV and APN
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inhibitors were added after 24 hours to adherent cells or directly to
PBMCs (1.25–20mM). 13-cis-RA (Sigma-Aldrich, Deisenhofen,
Germany) was added to SZ95 sebocytes under dimmed yellow light
at concentrations of 105 107 M. After further 48 hours (keratino-
cytes and sebocytes), 4 days (PBMCs stimulated with PHA) or 7 days
(PBMCs stimulated with P. acnes protein), the cultures were pulsed
for additional 6 hours with [3H]methyl-thymidine (0.2 mCi/well; ICN,
Meckenheim, Germany). The incorporated radioactivity harvested
on glass fiber filters was measured by scintillation counting.
Cytokine assays
For the generation of supernatants, 105 cells/ml (keratinocytes,
sebocytes) and 106 cells/ml (PBMCs) were seeded in 24-well plates
(Nunc, Wiesbaden, Germany). Inhibitors were added directly to
PBMC in concentrations of 10 mM. Adherent cells (keratinocytes and
sebocytes) were allowed to attach for 24 hours before the inhibitors
were added in concentrations of 50 or 100 mM. Supernatants
were collected 4, 24, and 48 hours after the inhibitor was added.
IL-1b, tumor necrosis factor-alpha, TGF-b1, IL-2, and IL-1RA were
measured using commercially available ELISA kits (R&D Systems,
Wiesbaden, Germany). IL-1a was determined using an EIA kit
obtained from PromoCell (Heidelberg, Germany).
Nile Red sebocyte differentiation assay
A subconfluent layer of 5 105 SZ95 sebocytes was incubated
for 48 hours in the presence of inhibitors in concentrations of 25
and 50 mM or 13-cis-RA at concentrations of 105–107 M. Cells were
dissociated with trypsin, incubated for 10 minutes with 1mg/ml Nile
Red (Sigma-Aldrich, Deisenhofen, Germany), washed twice
with phosphate-buffered saline, and analyzed immediately by
standard flow cytometric techniques using the FACSCalibur
(BectonDickinson, Heidelberg, Germany). Linoleic acid (Sigma-
Aldrich) was dissolved in ethanol to give a final concentration of
100mM in medium with 0.1% ethanol.
Lipid extraction and high-performance thin-layer
chromatography assessment of lipid fractions
SZ95 sebocytes were seeded into 6-cm Petri dishes (5 105 cells/
dish). Subconfluent cultures were incubated with inhibitors at a
concentration of 50 mM in serum-free medium for 48 hours or 13-
cis-RA at 105–107 M and then washed twice with phosphate-
buffered saline. Lipids were extracted with n-hexane/ethanol (95/5
(v/v)) under ultrasonication for 5 minutes. The extracts were filtered
and evaporated twice using a vacuum centrifuge (Univapo 150H,
Uniequip, Martinsried, Germany). For separation of the lipid mixture
into different classes, we used aminopropyl-bonded phase columns
(Supelco-Sigma, Munich, Germany). Lipid extracts were applied
in a volume of 200 ml chloroform to the n-hexane pretreated
columns. Squalene and wax esters were extracted in 3 ml n-hexane.
Triglycerides were subsequently extracted with 2 ml n-hexane/
methanol/chloroform (88/10/2¼ v/v), free fatty acids with 3 ml
diethyl ether/acetic acid (98/2), and cholesterol with 3 ml
n-hexane/ethylacetate (95/5). All lipid fractions were dried and
re-diluted in chloroform/methanol (2/1) before high-performance
thin-layer chromatography analysis carried out on 20 10 ml silica-
coated glass plates (Merck, Darmstadt, Germany). Samples were
applied to the n-hexane pretreated plates using a Linomat IV
(Camag, Berlin, Germany). Plates were developed to 5.5 cm in
n-hexane/diethyl ether/acetic acid (80/20/10), dried, and subse-
quently developed in petroleum benzene to full plate length. The
dried plates were dipped in a solution containing 10% CuSO4 and
8% H3PO4 and charred at 1801C for 15 minutes. Densitometric
quantification was performed using the CD 60 (Desaga, Heidelberg,
Germany) densitometer.
Statistical analysis
In the data sets demonstrated in Figures 3 and 6b, c the effects of
interest are (inhibitor) groups, dose and their interaction. In Figure 5,
the effects of interest are group, time, and their interaction. These
were determined by repeated measures analysis of variance using
the General linear model procedure of SAS, version 8.2 (SAS Institute
Inc., Minneapolis, MN).
In data sets comparing multiple (inhibitor) groups to a control
group (Figures 4 and 6c), one-way analysis of variance was
performed with subsequent post-tests if overall P-value was o0.05.
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